Lacritin, a Novel Human Tear Glycoprotein, Promotes Sustained Basal Tearing and Is Well Tolerated

Sandeep Samudre,1,2 Frank A. Lattanzio Jr,1,2 Victoria Lossen,1 Alireza Hosseini,1 John D. Sheppard Jr,1 Robert L. McKown,5 Gordon W. Laurie,4 and Patricia B. Williams1

PURPOSE. Lacritin is a novel human tear glycoprotein that promotes basal tear peroxidase secretion by rat lacrimal acinar cells in vitro. This study investigates whether lacritin is prospec-tory when added topically to the ocular surface of normal living rabbits, and if so, what is its efficacy and tolerability versus cyclosporine and artificial tears.

METHODS. Purified recombinant human lacritin (1, 10, 50, or 100 μg/mL), inactive lacritin truncation mutant C-25 (10 μg/mL), cyclosporine (0.05%), or artificial tears were topically administered to eyes of normal New Zealand White rabbits either as a single dose or three times daily for 14 days with monitoring of basal tear production. Basal tearing under proparacaine anesthesia was repeatedly assessed throughout and 1 week after chronic treatment ceased. Eyes were examined weekly by slit-lamp biomicroscopy.

RESULTS. Lacritin acutely increased basal tearing to 50% over vehicle at 240 minutes. Three times daily treatment with 10–100 μg/mL lacritin was well tolerated. Basal tearing became progressively elevated 4, 7, and 14 days later and was 50% over baseline (50 μg/mL lacritin) 1 week after treatment had ceased. Cyclosporine elevated tearing to a similar level on days 4 and 7 but had little or no effect on day 14 and had returned to baseline 1 week after ending treatment. C-25 and artificial tears had no effect.

CONCLUSIONS. Lacritin acutely stimulates basal tear flow that is sustained for at least 240 minutes. Two weeks of lacritin treatment three times daily was well tolerated and progressively elevated the basal tear flow. One week after treatment ended, basal tearing was still 50% over baseline. In contrast, cyclosporine triggered mild to moderate cornal irritation and a temporary elevation in tearing. (Invest Ophthalmol Vis Sci. 2011;52:6265–6270) DOI:10.1167/iovs.10-6220

Dry eye is the most common eye disease, affecting at least 5% of the world’s population, with higher prevalence in postmenopausal women (6%–9.8%)1 and the elderly (as high as 34%).2 Symptoms of this multifactorial disease include ocular surface discomfort and damage, tear film instability, problems with tear film evaporation, increased eye irritation by tear film, and inflammation, and elevated susceptibility to infection. The International Dry Eye Workshop Report3 distinguishes aqueous deficient (ADDE) and evaporative (EDE) dry eye and subcategories. ADDE is subdivided into Sjögren’s (primary/secondary) and non-Sjögren’s syndrome. Primary Sjögren’s syndrome is ADDE associated with autoantibodies, an inflammatory focal score in minor salivary glands and dry mouth with reduced salivation. Secondary Sjögren’s syndrome has added evidence of connective tissue autoimmune disease. The more common non-Sjögren’s syndrome ADDE is described as an aging-associated and autoimmune disease-independent lacrimal gland deficiency. EDE is excessive ocular surface water loss from evaporation, most commonly from blepharitis or meibomian gland dysfunction. Other causes include vitamin A deficiency (insufficient development of conjunctival goblet cells and lacrimal acinar cells), contact lens wear, topical drugs, and allergy.3

Treatment of dry eye is still at an early stage. Commonly used “artificial tears” temporarily alleviate symptoms of dry eye without addressing the cause. An ophthalmic formulation of the anti-angiogenic, increased tear epidermal growth factor, and inflammation-promoted for treatment of moderate to severe dry eye.4 Although two independent FDA phase 3 clinical trials involving 877 patients revealed a basal tearing benefit (Schirmer with anesthesia, 10 mm or more) in only 15% of dry eye patients versus 5% with placebo,4 subsequent studies have been more promising.5,6 Other proposed treatment approaches include topical vitamin A6, androgen,7 UTP analog INS365,8 and muscarinic agonist pilocarpine.9,10

The tear film is a rich source of growth factors, proteases, protease inhibitors, antioxidants,11 mucins, and lipids that has been only partially characterized. Future-capture ELISAs of specific tear proteins and tear proteomics together offer potentially useful indicators of the health of the ocular surface.12 Mechanisms underlying dysfunction might also be gleaned; for example, the lipophile lipocalin-113 and phospholipase A2 are increased in tears of patients intolerant to wearing contact lenses.14 Comparison of tears from Sjögren’s syndrome dry eye versus normal subjects by mass spectrometry revealed seven proteins peaks downregulated and three upregulated.15 Three human dry eye-related conditions have been scrutinized to date by unbiased screens coupled to proteomics and sequencing. Although HGF, IGF, NGF, and EGF can be detected in normal tears,16 lacritin was the only growth-like factor (and only one of nine tear proteins) downregulated of hundreds of proteins identified in tears from patients suffering from blepharitis.17 Blepharitis is a common inflammation of the eyelid, associated as noted above with EDE. The other eight downregulated proteins were albumin, Ig k chain-VII, pyruvate kinase, α1-antitrypsin, prolactin-inducible protein, cystatin SA-III, and lysozyme.18 Lactoferrin, lipocalin-1, lysozyme, and prolactin-inducible protein were reported to be downregulated in a screen.

From the 1Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, Virginia; 2Department of Integrated Science and Technology, James Madison University, Harrisonburg, Virginia; and 3Department of Cell Biology, University of Virginia, Charlottesville, Virginia.

1Contributed equally to the work and therefore should be considered equivalent authors.

Supported by Grants R42 EYO15376-05S109 (JDS) and R01 EYO18222 (GWL).

Submitted for publication July 14, 2010; revised September 17, 2010; accepted October 15, 2010.

Disclosure: S.S. Samudre, None; F.A. Lattanzio Jr, None; V. Lossen, None; A. Hosseini, None; J.D. Sheppard Jr, None; R.L. McKown, None; G.W. Laurie, P; P.B. Williams, None.

Corresponding author: Sandeep S. Samudre, Department of Physiological Sciences, Eastern Virginia Medical School, P.O. Box 1980, Norfolk, VA 23501; samudr@s.vms.edu.
of tears from patients with non-Sjögren’s syndrome dry eye.\textsuperscript{19} Recently Nichols and Green reported that lacritin is selectively downregulated more than any other tear protein in contact lens-related dry eye.\textsuperscript{15} Lacritin stimulates MUC16 production by human corneal epithelial cells at levels matching or exceeding that of serum (Laurie GE, et al. IOVS 2006;47:ARVO E-Abstract 1606). Autologous serum is a reportedly successful method of treating dry eye.\textsuperscript{20} Lacritin also promotes basal tear secretion by cultured rat\textsuperscript{21} and monkey\textsuperscript{22} lacrimal acinar cells and stimulates human corneal epithelial cell growth.\textsuperscript{23}

Lacritin is a 12.3 kDa secreted glycoprotein that is apically released from human lacrimal acinar cells during reflex tearing\textsuperscript{24,20} and can be detected in mixed reflex and basal human tears by ELISA\textsuperscript{23} and Western blotting.\textsuperscript{25} Lacritin is also produced by corneal, conjunctival,\textsuperscript{27} meibomian,\textsuperscript{28} and salivary epithelia as one of the most eye-restricted genes. Few cell types appear capable of being targeted by lacritin. Targeted cells include lacrimal acinar, salivary ductal/HeLa, human corneal, and embryonic kidney cells, but no others among 17 different cell lines tested.\textsuperscript{23} Its co-receptor syndecan-1 is widely expressed on ocular surface epithelia.\textsuperscript{29} Thus, lacritin appears to be a multifunctional eye-specific factor with a potential role in tear secretion and corneal epithelial renewal. Here we ask whether lacritin promotes tearing when administered topically to eyes of normal rabbits. We observe that a single dose of lacritin or lacritin chronically administered for 2 weeks elevates basal tearing. The latter is remarkably sustained for 1 week after treatment ended.

**Materials and Methods**

**Animals**

A total of 18 age- and weight-matched New Zealand White adult female rabbits (3–5 kg) with normal eyes and no ocular pathology were used in this study. Experiments were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and were approved by the Eastern Virginia Medical School Institutional Animal Care and Use Committee. Animals were acclimated for 1 week before experimentation.

**Recombinant Lacritin and C-25**

Human recombinant lacritin and a lacritin truncation mutant lacking 25 amino acids from its C terminus (C-25) were cloned into bacteria expression plasmids as previously described.\textsuperscript{25} For protein expression, cultures of *E. coli* strain ER2566 harboring the plasmid of interest were grown to midlog (37°C), induced with 0.5 mM isopropanol-D-thiogalactopyranoside for 4 hours (25°C), and harvested by centrifugation. Cell pellets frozen at −70°C were thawed at room temperature, lysed by sonication in 50 mM Tris (pH 8), 0.5 M NaCl, 0.45% Triton X-100, and centrifuged. Supernatant was loaded onto chitin columns (IMPACT-CN System, New England Biolabs, Ipswich, MA) equilibrated with 10 column volumes of 50 mM Tris (pH 8), 0.5 M NaCl. Columns were washed with 20 column volumes of the same buffer. On-column cleavage of lacritin or C-25 from C-terminal intein was accomplished by incubation for 16 hours at room temperature with 0.39% (V/V) 2-mercaptoethanol in the same buffer. Eluates were concentrated by ultrafiltration and dialyzed extensively against PBS (4°C). The concentrated and dialyzed chitin fraction was loaded onto a fast-flow column equilibrated with PBS (DEAE Sepharose Fast Flow; GE Healthcare, Uppsala, Sweden). The unbound flow through was collected and assayed for total protein concentration by the BCA assay and purity by SDS PAGE (Fig. 1). Aliquots were frozen, lyophilized, and stored at −70°C. To prepare topical eye drops, lacritin was dissolved under aseptic conditions in sterile water.

**Cyclosporine and Artificial Tears**

Cyclosporine (0.05%, Restasis; Allergan, Irvine, CA) and artificial tears (Refresh Tears; Allergan) were purchased from local pharmacies.

**Figure 1.** SDS PAGE of purified lacritin. Lane 1: molecular weight markers; lane 2: purified lacritin. Coomassie blue staining.

**Tear Fluid Analysis**

Before experimentation, baseline tear flow, intraocular pressure, and tear composition were assessed. Eyes were first anesthetized for 10 minutes with 0.5% proparacaine to minimize reflex tearing (Fig. 2) and then polyester wicks (Filtrona R15643; Company, Colonial Heights, VA) or calibrated Schirmer strips (TearFlo; Rose Stone Enterprises, Alta Loma, CA) were placed in the medial canthus for 1 minute. We refer to tears collected with anesthetic as ‘basal tears’ and their production as ‘basal tear secretion.’ Rabbits were randomly assigned to receive 50 μL in each eye of lacritin (1, 10, and 50 μg/mL), C-25 (10 μg/mL), 0.05% cyclosporine, or artificial tears. In acute studies, basal tear flow was bilaterally measured 60, 120, and 240 minutes after agonist addition. In chronic studies, eyes were treated three times daily for 14 days, and then basal tear flow was measured with Schirmer strips after 4, 7, and 14 days of treatment, and 7 days after treatment had stopped. Basal tears were collected 60, 120, and 240 minutes after the morning dose of lacritin, C-25, cyclosporine, or artificial tears. Data were then averaged as the ‘daily tear flow.’ Tears were eluted by soaking wicks for 20 minutes in 30 μL of deionized water (conductivity 18 μS), followed by centrifugation at 13,000 rpm for 10 minutes. Tear pH, sodium, and potassium were respectively monitored with microelectrodes MI-410, MI-420, and MI-442 (Microelectrodes, Inc., Bedford, NH). Protein concentration was determined using a BCA protein assay (Thermo Scientific/Pierce, Rockford, IL), which was linear from 0.025 to 2.0 μg/μL at 570 nm (PowerWaveX microplate spectrophotometer, Bio-Tek Instruments Inc., Winooski, VT).

**Ocular Surface Analysis**

Before and after treatment, rabbits were lightly sedated with acepromazine (2.5 mg/kg) and ketamine (25 mg/kg), and then all eyes were examined by slit-lamp biomicroscopy (HAAG-STREIT, Bern, Switzerland) using a semiquantitative modified McDonald-Shadduck scale for ocular irritation and inflammation.\textsuperscript{30} Evaluations were performed by an independent knowledgeable observer. Parameters included conjunctival congestion, swelling, and discharge, aqueous flare/anterior chamber reaction, loss of light reflex, iris hyperemia, corneal opacity, and vascularization. Each parameter was rated on a four-point scale, where zero represents normal.

**Intraocular Pressure Analysis**

Intraocular pressure was monitored using pneumotonometry (Mentor, Norwalk, MA) in rabbits lightly sedated with acepromazine (2.5 mg/kg) and ketamine (25 mg/kg). Two consecutive measurements made at the same time of day by the same observer were averaged.
Statistical Analysis

Results are reported as the mean ± SE. Data were analyzed by paired t-test or ANOVA as appropriate. Differences were considered significant at P < 0.05.

RESULTS

Basal Tearing after Treatment with Lacritin, C-25, Artificial Tears, or Cyclosporine

We initially optimized 0.5% proparacaine anesthesia to thoroughly block irritation-induced reflex tearing associated with wick or Schirmer strip insertion. Without anesthesia, Schirmer strips collected 17.7 ± 2.1 mm (n = 6) of rabbit tears in 1 minute, a value representing mixed basal and reflex tears. However, 10, 20, and 30 minutes after proparacaine, strips collected 11.3 ± 3.4, 14.2 ± 2.7, and 17.3 ± 8.3 mm (n = 6) of rabbit tears, respectively. These data indicated that proparacaine was most effective at 10 minutes (P = 0.05) or less. Thereafter reflex tearing gradually resumed (Fig. 2A) in keeping with the brevity of proparacaine anesthesia. We wished to assess basal tearing at multiple time points and wondered whether an interval as short as 60 minutes was appropriate. To address this question (Fig. 2A), proparacaine was administered 10 minutes before tear collection at each of 0, 60, 120, and 240 minutes later. Basal tear flow was 10.3 ± 4.1 mm at 0 min (n = 6) and remained essentially unchanged at each subsequent time point. At 240 minutes, for example, it was 10.4 ± 2.6 mm (n = 6). However, in the absence of proparacaine, tear flow was 16.2 ± 1.9 mm (n = 6) at 0 min. Flow increased after Schirmer strips were inserted at 60 and 120 minutes, but not after 240 minutes (Fig. 2B). Taken together, basal tear collection 10 minutes after initiating proparacaine anesthesia and at 60-minute intervals are appropriate for analysis of basal tearing. To address whether lacritin was a basal tear agonist, lacritin (50 μg/mL) was topically administered to the right eyes. Left eyes received PBS (vehicle) alone. Tear flow was subsequently measured at 60, 120, and 240 minutes with anesthesia. Lacritin significantly increased basal tear flow over baseline at each time point (n = 6; P < 0.01) and exceeded the vehicle by 30% at 240 minutes (Fig. 3; n = 6; P < 0.001).

Although basal tearing is elevated for at least 240 minutes after a single lacritin dose, we wished to know whether the response might diminish with repeated treatment and whether there was a concentration effect. To address these questions, eyes were topically treated with 1, 10, 50, or 100 μg/mL of lacritin three times daily for 14 days. Basal tears were collected during the course of treatment at 0, 4, 7, and 14 days. To explore possible long-term effects, tears were also collected 7 days after lacritin treatment had ended (Fig. 4). Instead of a loss of effect, basal tearing became progressively elevated and displayed a concentration dependant response with a lacritin dose optimum of 50 μg/mL. More unexpectedly, basal tearing was 50% over baseline (P < 0.001, n = 6) 1 week after lacritin treatment had ceased. This latter effect (possibly trophic) displayed an approximate EC_{50} of 10 μg/mL (Fig. 5) when max-
imum basal tear flow was plotted versus log dose. Thus single doses of lacritin given repeatedly have a benefit that is sustained after washout.

Although our rabbits were not suffering from autoimmune dry eye, a question left unanswered by Toshida32 was whether 0.05% cyclosporine might alter basal tearing, and if so how might tearing compare to eyes treated with artificial tears, lacritin, or inactive lacritin C-25. C-25 lacks the syndecan-1 binding domain necessary for lacritin cell targeting.33 Eyes received topical 0.05% cyclosporine, artificial tears, lacritin, or C-25 lacritin three times daily over 2 weeks with parallel basal tear collection at 0, 4, 7, and 14 days, and then 7 days after treatment ended (Fig. 6). Despite proparacaine anesthesia, cyclosporine stimulated a transient but rapid rise in basal tearing that formed a plateau at days 4 and 7 and then subsequently fell off to baseline by 7 days posttreatment. Artificial tears and C-25 had no effect. This contrasted with lacritin that again promoted a steady rise in basal tearing. Remarkably, lacritin-dependent tearing was sustained for 7 days posttreatment.

**Lacritin Tolerability, Tear Composition, and Intraocular Pressure (IOP) Assessment**

To assess relative lacritin tolerability, eyes were treated three times daily for 14 days with lacritin, cyclosporine, or artificial tears and examined with a slit-lamp. Ocular irritation was then graded using the semiquantitative modified McDonald-Shadduck scale. Lacritin is well tolerated after 14 days of treatment three times daily (Table 1). Mild conjunctival congestion was observed in all groups after 14 days of treatment. However, neither lacritin nor C-25 treatment stimulated conjunctival swelling or discharge, aqueous flare/anterior chamber reaction, loss of light reflex, iris hyperemia, or corneal opacity or vascularization. Lacritin did not cause corneal vascularization, which suggests lack of cross-talk with VEGF signaling. Also tear composition after chronic lacritin treatment was consistent with normal tears as tear sodium, potassium, pH, and protein concentration levels were unaffected. Tear composition was assessed by measuring the sodium, potassium, and total protein content of tears before and after lacritin (100 μg/mL) single dose treatment. These measurements remained within normal limits and were not different from baseline IOP, and were maintained at an average value of 17.0 ± 0.9 mm Hg throughout the study (Table 2). In contrast, significant conjunctival discharge and iris hyperemia were noted after cyclosporine treatment. IOP in lacritin-treated eyes was also unchanged.

**DISCUSSION**

We document that administration of lacritin to the eye stimulates basal tear flow in rabbits. Flow is elevated for at least 240
Protein 39
Potassium 23

TABLE 2. Sodium 116

involvements, referred to as synapse-like structures, through chick cornea are enveloped in specialized epithelial membrane


minutes after a single dose. Eyes treated three times daily for 2 weeks display a steady rise in tearing that is remarkably sustained for at least 1 week after the last treatment and is well tolerated. Cyclosporine transiently increases basal tearing, apparently coincident with elevated ocular surface irritation.

As a normal component of human tears, lacritin flows from the lacrimal gland onto the ocular surface with contributions from the meibomian gland, conjunctiva, and cornea. In cell culture, lacritin stimulates calcium signaling within seconds and subsequently promotes proliferation of subconfluent human corneal epithelial cells. It also induces NFAT and mTOR mitogenic signaling in HSG/HeLa cells via heparanase-dependent binding of the cell surface proteoglycan syndecan-1 and activation of a G-protein coupled receptor. Both heparanase and syndecan-1 are expressed throughout the normal corneal epithelia, and heparanase has been detected in normal tears (Ma P and Laurie GW, unpublished, 2006).

Although a tear protein itself, how might lacritin increase ocular surface wetting by promoting basal tearing? In unpublished studies, lacritin induces protein expression of the hydrophilic membrane mucin MUC16 (Laurie GE, et al. IOVS 2006;47: ARVO E-Abstract 1606), which is necessary for ocular surface wetting. For basal tearing, an immediate consideration is whether lacritin may directly stimulate corneal sensory neurons, possibly via a G-protein coupled receptor as a negative or positive modulator of a transient receptor potential (TRP) cationic channel. As an example, alpha 2A adrenoreceptor activation inhibits the TRPM8 innocuous cold receptor in rat dorsal root ganglion sensory neurons. Alternatively, sensory neurons could be indirectly activated by lacritin. Sensory nerve endings in human and chick cornea are enveloped in specialized epithelial membrane invaginations, referred to as synapse-like structures, through which mediators might be released after lacritin-stimulated corneal epithelial cell signaling. Sensory neurons penetrate the corneal epithelium to form the afferent arm of the lacrimal functional unit. Although incompletely understood at the molecular level, corneal sensory neurons detect and convey delicate or dramatic changes in ocular surface temperature, hyperosmolality, chemical irritation, and mechanical pressure to the brain stem’s lacrimal nucleus. Preganglionic parasympathetic axons originating from the lacrimal nucleus then promote lacrimation commensurate with the level of the efferent signal, with low levels sufficient for basal tearing. It is also possible that lacritin might target corneal water or ion transport that are each subject to regulation by different agonists, for example, by altering the cellular distribution of aquaporin-2.

Notably, basal tearing was elevated 1 week after chronic lacritin treatment ended. Perhaps lacritin is trophic for sensory neurons, particularly in the context of a germinative corneal epithelium that is being continually renewed. Neuronal sensitivity, differentiation, and axonal stabilization are in part G-protein coupled receptor dependent, and targeting of the alpha 2 adrenoreceptor promotes signaling that transactivates nerve growth factor receptor NTRK1. The sustained effect of lacritin contrasts with other ocular surface therapeutics. Artificial tears had no effect on basal tearing, and cyclosporine elevated basal tearing only temporarily and was irritating. It should be noted that a longer-term treatment (>4 weeks) is recommended for dry eye patients and may produce more relief. Although the rationale for cyclosporine is to suppress inflammatory dry eye, a condition not experienced by our rabbits, others have noted that cyclosporine secondarily provokes a transient rise in tear flow collected without anesthesia in rabbits. Cyclosporine has no effect when added to cultured lacrimal gland fragments. Since flow in rabbits is augmented by lacrimal gland parasympathetic nerves, Yoshida et al. proposed an effect on reflex tearing from irritation. With the strength of the parasympathetic signal controlling the level of lacrimation, an alternative interpretation is that the effect was at the level of basal tearing. Unfortunately, tears were collected in the absence of ocular surface anesthesia.

In summary, lacritin is a natural human protein with unique properties. Addition of recombinant lacritin to the ocular surface alone or in combination with other agonists may help restore a natural tear film, particularly under dry eye conditions where lacritin or elements of its cell targeting mechanism may be deficient.

Acknowledgments

The authors thank Patricia Loose-Thurman, Natasha Gandia, Daneca Campbell, Kristen Pelosky, and Scott Eubank for their technical assistance; and Cassandra Sherry for critical review of this manuscript.

Table 1. Slit-Lamp Analysis and McDonald-Shadduck Scale for Ocular Irritation

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Baseline (n = 6)</th>
<th>Lacritin (100 µg/mL)</th>
<th>Cyclosporine (0.05%)</th>
<th>Artificial Tears*</th>
<th>C-25 (10 µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conjunctival congestion</td>
<td>0 ± 0.2</td>
<td>1 ± 0.1</td>
<td>1.5 ± 0.4</td>
<td>1 ± 0.1</td>
<td></td>
</tr>
<tr>
<td>Conjunctival swelling</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Conjunctival discharge</td>
<td>0 ± 0.3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Aqueous flare</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Light reflex</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Iris hyperemia</td>
<td>1 ± 0.3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>% Corneal opacity</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>% Corneal vascularization</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

Individual parameters were graded on a scale of 0 to 4, where 0 = normal. All values are mean ± SE.

* Proprietary non-prescription formula (Refresh Tears; Allergan).

Table 2. Effect of 14-Day Lacritin (100 µg/mL) Administration on Tear Quality, and Intraocular Pressure (IOP) as Compared with Baseline

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Baseline (n = 6)</th>
<th>Lacritin (100 µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>8.1 ± 1.2</td>
<td>7.6 ± 0.8</td>
</tr>
<tr>
<td>Sodium</td>
<td>116 ± 18 mM</td>
<td>87 ± 10 mM</td>
</tr>
<tr>
<td>Potassium</td>
<td>25 ± 4 mM</td>
<td>18 ± 3 mM</td>
</tr>
<tr>
<td>Protein</td>
<td>39 ± 3 µg/µL</td>
<td>32 ± 8 µg/µL</td>
</tr>
<tr>
<td>IOP</td>
<td>17.0 ± 0.9 mm Hg</td>
<td>17.0 ± 1.4 mm Hg</td>
</tr>
</tbody>
</table>

n = 6.
References


Downloaded From: https://iovs.arvojournals.org/ on 10/13/2018